Title:
CRYSTAL FORMS OF FXR RECEPTOR AGONIST
Document Type and Number:
WIPO Patent Application WO/2022/179636
Kind Code:
A1
Abstract:
The present invention relates to crystal forms I, II, III, IV, V, VI, VII, VIII, and IX of an FXR receptor agonist 2-((1S,4S,5R)-5-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-azabicyclo[2.2.1]heptane-2-yl)benzo[d]thiazole-6-carboxylic acid, and a preparation method therefor. The crystal forms have the characteristics of high purity, less residual solvent, high solubility, good disintegration and dissolution properties, good stability and the like, and the crystal forms have good properties, fluidity and compressibility, and are convenient for production, detection, formulation preparation, transportation and storage; the preparation method is simple and convenient to operate and is suitable for industrial production, and the crystal forms can be used for treating and/or preventing FXR-mediated related diseases.
Inventors:
LIU BIN (CN)
YANG QIANG (CN)
LI JICHENG (CN)
YANG QIANG (CN)
LI JICHENG (CN)
Application Number:
PCT/CN2022/078142
Publication Date:
September 01, 2022
Filing Date:
February 28, 2022
Export Citation:
Assignee:
XUANZHU BIOPHARMACEUTICAL CO LTD (CN)
International Classes:
C07D417/14; A61K31/422; A61K31/428; A61K31/439; A61P1/00; A61P3/00; A61P7/02; A61P9/10; C07D413/14
Domestic Patent References:
| WO2019007418A1 | 2019-01-10 | |||
| WO2020033382A1 | 2020-02-13 |
Foreign References:
| CN110177783A | 2019-08-27 |
Download PDF: